<div id="readability-page-1"><p><span>CARGO Therapeutics (NASDAQ:CRGX - Get Free Report)</span> was downgraded by equities research analysts at HC Wainwright from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a research note issued to investors on Thursday, Marketbeat Ratings reports.</p><div><p><span></span><span>Get <strong>CARGO Therapeutics</strong> alerts:</span></p></div><ul><li>IPO watch 2024: Which new stocks will hit the market?</li></ul><p>A number of other equities analysts also recently issued reports on CRGX. Chardan Capital  restated a &#34;buy&#34; rating and issued a $28.00 price target on shares of CARGO Therapeutics in a research note on Wednesday, November 13th. William Blair assumed coverage on CARGO Therapeutics in a report on Tuesday, November 26th. They issued an &#34;outperform&#34; rating on the stock. One investment analyst  has rated the stock with a sell rating and six have assigned  a hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and a consensus target price of $15.00.</p><p><b>Read Our Latest Research Report on CARGO Therapeutics</b></p><h2>CARGO Therapeutics Stock Performance</h2><p>NASDAQ CRGX opened at $13.19 on Thursday. The company has a market capitalization of $607.14 million, a price-to-earnings ratio of -3.10 and a beta of 2.50. The stock has a 50-day moving average of $14.83 and a 200 day moving average of $17.45. CARGO Therapeutics has a one year low of $10.91 and a one year high of $33.92. </p><p>CARGO Therapeutics (NASDAQ:CRGX - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.26.  On average, equities analysts predict that  CARGO Therapeutics will post -3.73 earnings per share for the current fiscal year. </p><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds have recently made changes to their positions in CRGX. FMR LLC lifted its holdings in  CARGO Therapeutics by 1.1% during the third quarter. FMR LLC now owns 6,954,476 shares of the company's stock valued at $128,310,000 after purchasing an additional 77,508 shares in the last quarter.  RTW Investments LP raised its position in shares of  CARGO Therapeutics by 0.5% during the 3rd quarter. RTW Investments LP now owns 4,098,955 shares of the company's stock valued at $75,626,000 after purchasing an additional 20,833 shares during the period.  Janus Henderson Group PLC lifted its stake in shares of  CARGO Therapeutics by 1.8% during the 3rd quarter. Janus Henderson Group PLC now owns 2,675,285 shares of the company's stock valued at $49,335,000 after buying an additional 46,659 shares in the last quarter.  Wellington Management Group LLP boosted its holdings in  CARGO Therapeutics by 4.1% in the 3rd quarter. Wellington Management Group LLP now owns 2,042,723 shares of the company's stock worth $37,688,000 after buying an additional 79,782 shares during the period.  Finally, State Street Corp increased its stake in  CARGO Therapeutics by 11.7% in the 3rd quarter. State Street Corp now owns 839,861 shares of the company's stock worth $15,495,000 after buying an additional 88,000 shares in the last quarter. 93.16% of the stock is currently owned by institutional investors. </p><h2>About CARGO Therapeutics</h2> (Get Free Report)<p>CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than CARGO Therapeutics</li><li>Stock Market Sectors: What Are They and How Many Are There? </li><li>Kimberly-Clark: A Regal Opportunity in This Dividend King</li><li>3 Small Caps With Big Return Potential</li><li>5 Stocks With Above-Market Yields Just Raised Payments Further</li><li>Using the MarketBeat Dividend Yield Calculator</li><li>Arista Networks' Stock Plunge: Buying Opportunity for Investors?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JHWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CARGO Therapeutics Right Now?</h2><p>Before you consider CARGO Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CARGO Therapeutics wasn't on the list.</p><p>While CARGO Therapeutics currently has a &#34;Reduce&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CRGX

<p>CARGO Therapeutics (NASDAQ:CRGX) has been downgraded from a "buy" to a "neutral" rating by HC Wainwright. The company has an average rating of "Hold" and a consensus target price of $15.00. CARGO's stock opened at $13.19, with a market cap of $607.14 million. Recent quarterly earnings showed a loss of ($0.88) per share, beating estimates. Institutional investors hold 93.16% of the stock, indicating strong institutional interest despite the downgrade.</p>

CARGO Therapeutics (NASDAQ:CRGX) Lowered to "Neutral" Rating by HC Wainwright